China Looms Large Seeking New Funding, Deals At J.P. Morgan
Chinese biotech companies are raising their profile and increasing their appeals to investors and partners at the J.P. Morgan Healthcare Conference. After billions in investment and increased activity in M&As, China is likely to remain attractive for international companies large and small vying for a slice of investment or pursuing innovative therapies.
You may also be interested in...
Poseida and Legend/Janssen aim to develop CAR-T therapies with improved efficacy and safety, and both programs delivered updates at ASH for BCMA-targeting CAR-T candidates in multiple myeloma that could challenge Celgene/bluebird's lead in this field.
An autologous CAR-T therapy in development by Janssen and Legend Biotech is expected to kick-off US clinical studies in the second half of 2018, adding to the race to apply the new technology to multiple myeloma.
Zai Lab's VP and Head of Business Development Jonathan Wang tells Brain Yang how the China FDA's regulatory reforms make China attractive to international biotechs, and that therapeutic areas such as oncology and anti-infectives are to benefit, along with partnering in China.